Access to the Dapivirine Vaginal Ring: A timeline on progress
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.
CAB-LA Trials at a Glance
This infographic shares a breakdown of the current injectable CAB for PrEP trials including ongoing sub-studies.
Time to Develop a Vaccine
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. This graphic is excerpted from Vaccines by the Numbers: Trials, discoveries, money and more.
Efficacy Study Design
This graphic details the trial design behind HPTN 083 and HPTN 084, two-large scale efficacy trials testing cabotegravir, an antiretroviral formulated as an injectable for long-lasting pre- exposure prophylaxis (PrEP).
To learn more, read An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP.
Research Fundamentals: What is an endpoint?
The next installment of our Px Pulse series Research Fundamentals, explaining key concepts in HIV prevention research, is up. In this episode, Px Pulse host Jeanne Baron and Matthew Rose, a veteran HIV advocate and now Director at Global Health Strategies, look at endpoints in research.
Endpoints are a crucial component in every clinical trial but they are not always well understood. In addition, advocates can and should play a role, reviewing endpoints and interrogating how well the trial will serve communities that need HIV prevention.
Joining us to explore all this are:
- Dave Glidden, Professor of Epidemiology & Bio-statistics at UC San Francisco
- Erica Lessem, Senior Strategist for NYC Dept. of Health and Mental Hygiene, former Deputy Executive Director, Treatment Action Group
- Meagan O’Brien, Senior Medical Director of Early Clinical Development & Clinical Experimental Sciences at Regeneron
Listen to learn how endpoints are used in clinical research, why they change overtime, and what matters most about endpoints for advocates and researchers alike.
AVAC’s Strategic Plan 2022-2026
AVAC’s strategic framework is grounded in a multi-layered approach that carefully considers all of the components needed to achieve the organization’s vision, capitalize on its key strengths, and ensure that AVAC is poised to make an impact on the issues it cares most about over the next five years, and beyond.
The vision describes the world we are striving for. The mission describes what AVAC does in service to achieving this vision. The strategic pillars outline the objectives and approaches that AVAC will take over the next five years to achieve its mission and vision. The strategic pillars are supported by AVAC’s core values—the principles by which we work—as well as a set of key enablers.
Advocate, Translate, Catalyze: For HIV prevention and health equity
In this document, we look at the actions we are taking and those that as a field we all need to take to transform prevention “options” developed through research into prevention “choices” for people that can save lives and help end epidemics. This work is critical, and it is shared – just as we developed our strategic plan and EDI statement in partnership with so many, so too will we move this work forward, together.